Health professionals need to be aware of the current approach to the treatment of HIV infection as more Australians are living with HIV/AIDS. Approximately half of these patients are taking combination antiretroviral therapy. These regimens have a wide range of adverse effects and interactions. The prevalence of HIV infection is expected to increase, not only because the incidence is increasing, but also because effective antiretroviral therapy is prolonging survival. People living with HIV/AIDS are increasingly likely to seek care from doctors without a special interest in HIV because of increasing comorbidities including cardiovascular disease.
Introduction
Treatment with a combination of antiretroviral drugs prevents the progression of human immunodeficiency virus (HIV) disease by inhibiting viral replication. 1 It also stops the associated immunological deterioration associated with the depletion of CD4 lymphocytes. Effective inhibition of HIV replication may even restore the patient's immune system. Adherence to twice-daily doses is better than to thrice-daily doses, although adherence to twice-daily and once-daily doses appears equivalent. 
Principles of management

Cardiovascular disease
Antiretroviral therapy appears to be an independent risk factor for ischaemic coronary events. In a prospective observational multicentre study with more than 30 000 patient years of follow-up, each year of therapy was associated with a 26% increased risk of myocardial infarction. 3 This has resulted in a greater focus on strategies to reduce risk factors for ischaemic 
New protease inhibitors
These drugs prevent viral replication by inhibiting the proteases in HIV.
Atazanavir
Atazanavir has efficacy in previously untreated patients and in those who have previously taken protease inhibitors. 5 The recommended dose is either 400 mg daily, or 300 mg daily when boosted with ritonavir 100 mg daily. Atazanavir must be boosted with ritonavir when used in protease inhibitorexperienced patients or when used in combination with tenofovir, as tenofovir decreases atazanavir concentrations.
Atazanavir is approved for once-daily dosing.
The main advantage of atazanavir over other protease inhibitors is that it is not associated with significant insulin resistance or elevation in serum lipid levels. However, it can cause unconjugated hyperbilirubinaemia. Some patients develop scleral icterus that may be cosmetically unpleasant, but less than 1% of patients in clinical trials ceased atazanavir because of this adverse effect.
Atazanavir should be taken with food. Its absorption is significantly decreased by reductions in gastric acidity. Drugs that reduce gastric acidity may decrease the concentrations of atazanavir. Proton pump inhibitors should therefore not be given to patients taking atazanavir.
Fosamprenavir
Fosamprenavir is the most recently approved protease inhibitor in Australia. When boosted with ritonavir it has efficacy in treated and previously untreated patients. 6 The recommended dose is 700 mg twice a day administered with 100 mg ritonavir twice a 
Tipranavir
Tipranavir is a 'second-generation' protease inhibitor. It is active against a wide variety of isolates which are resistant to the other currently available protease inhibitors. Tipranavir is only available on the Special Access Scheme in Australia.
Emtricitabine
Emtricitabine (FTC) is a potent cytidine nucleoside analogue with a long plasma half-life. It has efficacy as part of a once-daily regimen for previously untreated patients. 7 The recommended dose is 200 mg once daily, but dose adjustments are required for patients with renal impairment. 
Enfuvirtide
Enfuvirtide (T20) is the first HIV fusion inhibitor to be licensed for use in clinical practice. It inhibits the fusion of the viral and human cell membranes following viral attachment (see Fig. 1 ).
Given its novel site of action enfuvirtide has significant antiviral activity against isolates which have resistance to other drug classes. Its benefit is maximised if used with other active drugs, however its role in contemporary practice is limited by the fact that it needs to be injected subcutaneously twice daily.
Injection site reactions are common, but not usually dose limiting. Hypersensitivity reactions can occur.
Conclusion
The therapy of HIV infection continues to change. Clinicians need to be aware of developments in this field, as they are increasingly likely to need to provide care to people living with HIV/AIDS.
